260
Views
1
CrossRef citations to date
0
Altmetric
Patent Evaluations

Evaluation of WO2012080456 and WO2012080457; Boheringer Ingleheim's first CXCR2 antagonists

, MBA PhD
Pages 383-388 | Published online: 16 Jan 2013

Bibliography

  • Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977;1(6077):1645-8
  • Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis 2012;7:95-9
  • Barnes PJ. New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin Immunol 2007;119(5):1055-62
  • Stockley RA. Progression of chronic obstructive pulmonary disease: impact of inflammation, comorbidities and therapeutic intervention. Curr Med Res Opin 2009;25(5):1235-45
  • Pease JE, Sabroe I. The role of interleukin-8 and its receptors in inflammatory lung disease: implications for therapy. Am J Respir Med 2002;1(1):19-25
  • Pease JE, Horuk R. Chemokine receptor antagonists: part 2. Expert Opin Ther Pat 2009;19(2):199-221
  • Busch-Petersen J, Wang Y. Phenol-containing antagonists of the CXCR2 receptor. Expert Opin Ther Pat 2008;18(6):629-37
  • White JR, Lee JM, Young PR, Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 1998;273(17):10095-8
  • SmithKline Beecham Corp. IL-8 Receptor Antagonists. WO1996025157; 1996
  • Dwyer MP, Yu Y, Chao J, Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist. J Med Chem 2006;49(26):7603-6
  • Boehringer Ingelheim International GmbH. Bicyclic ring system substituted amide functionalised phenols as medicaments. WO2012080456; 2012
  • <patnet>Boehringer Ingelheim International GmbH. Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments. WO2012080457; 2012
  • Pharmacopeia, Inc. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands. US20040097547; 2004
  • Novartis AG. 3,4-Di-substituted cyclobutene-1,2-diones as CXCR2 receptor antagonists. WO2010063802; 2010
  • Novartis AG. Oragnic compounds. WO2010015613; 2010
  • Gonsiorek W, Fan X, Hesk D, Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. J Pharm Exp Ther 2007;322:477-85
  • Chapman RW, Minnicozzi M, Celly CS, A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J Pharmacol Exp Ther 2007;322(2):486-93
  • Holz O, Khalilieh S, Ludwig-Sengpiel A, SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur Respir J 2010;35(3):564-70
  • Nair P, Gaga M, Zervas E, Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy 2012;42(7):1097-103
  • Ligand Pharmaceuticals, Inc. Presentation For Investor And Analyst Day - June 24, 2010
  • Available from: http://clinicaltrials.gov Long-Term Extension Study of the Effects of SCH 527123 in Subjects With Moderate to Severe COPD (P05575AM2)(MK-7123-009-0) NCT01006616 (1 December 2011)
  • Wolff M, Kredel S, Haasen D, High content screening of CXCR2-dependent signalling pathways. Comb Chem High Throughput Screen 2010;13(1):3-15

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.